Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Immune checkpoint modulation is a significant advancement in treating solid tumors.
• This approach offers improved patient outcomes and a better side effect profile compared to traditional chemotherapy.

Purpose of the Study:

• To review current monoclonal antibody therapies targeting immune checkpoints.
• To discuss their history, mechanisms, clinical applications, and supporting data.
• To explore challenges in achieving durable tumor responses and potential solutions.

Main Methods:

• Literature review of existing clinical data and research on immune checkpoint inhibitors.
• Analysis of monoclonal antibodies currently used in cancer treatment.
• Examination of factors limiting treatment efficacy and proposed interventions.

Main Results:

• Monoclonal antibodies targeting immune checkpoints are established cancer therapies.
• These therapies have demonstrated efficacy in various solid malignancies.
• Challenges remain in overcoming treatment resistance and enhancing durable responses.

Conclusions:

• Immune checkpoint inhibitors represent a key therapeutic strategy in oncology.
• Understanding their mechanisms and limitations is crucial for optimizing patient care.
• Further research is needed to address barriers to sustained tumor regression.